BridgeBio Pharma, Inc. (BBIO)
78.17
-1.37
(-1.72%)
USD |
NASDAQ |
Nov 12, 16:00
78.40
+0.23
(+0.29%)
After-Hours: 07:42
BridgeBio Pharma Debt to Equity Ratio : -2.054 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | -2.054 |
| June 30, 2026 | -1.353 |
| March 31, 2026 | -1.486 |
| December 31, 2025 | -1.308 |
| September 30, 2025 | -1.399 |
| June 30, 2025 | -1.497 |
| March 31, 2025 | -1.430 |
| December 31, 2024 | -1.505 |
| September 30, 2024 | -1.406 |
| June 30, 2024 | -1.582 |
| March 31, 2024 | -1.647 |
| December 31, 2023 | -1.285 |
| September 30, 2023 | -1.437 |
| June 30, 2023 | -1.273 |
| March 31, 2023 | -1.411 |
| December 31, 2022 | -1.374 |
| Date | Value |
|---|---|
| September 30, 2022 | -1.507 |
| June 30, 2022 | -1.669 |
| March 31, 2022 | -1.660 |
| December 31, 2021 | -1.985 |
| September 30, 2021 | -1.884 |
| June 30, 2021 | -3.011 |
| March 31, 2021 | -3.497 |
| December 31, 2020 | 8.562 |
| September 30, 2020 | 2.954 |
| June 30, 2020 | 1.804 |
| March 31, 2020 | 1.241 |
| December 31, 2019 | 0.2443 |
| September 30, 2019 | 0.1632 |
| June 30, 2019 | -1.753 |
| March 31, 2019 | -2.353 |
| December 31, 2018 | -3.252 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Ionis Pharmaceuticals, Inc. | 5.520 |
| Pfizer Inc. | 0.7042 |
| Cytokinetics, Inc. | -3.962 |
| Vertex Pharmaceuticals, Inc. | 0.3099 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.162B |
| Total Liabilities (Quarterly) | 3.815B |
| Shareholders Equity (Quarterly) | -1.662B |
| Current Ratio | 2.092 |
| Net Debt Paydown Yield | -1.14% |